Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
https://www.zacks.com/stock/news/2203052/biotech-stock-roundup-bmy-s-krtx-and-ryzb-acquisition-cytk-surges-on-study-data?cid=CS-ZC-FT-analyst_blog|stock_roundup-2203052
Dec 28, 2023 - Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.
0
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
https://www.zacks.com/stock/news/2202718/fda-rejects-amgen-s-amgn-nda-seeking-full-nod-for-lumakras?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202718
Dec 27, 2023 - Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
0
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
https://www.zacks.com/stock/news/2202697/astrazeneca-azn-set-to-acquire-gracell-for-1-2-billion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202697
Dec 27, 2023 - AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
0
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
https://www.zacks.com/stock/news/2202691/bristol-myers-bmy-to-buy-cancer-drug-maker-rayzebio-for-4-1b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202691
Dec 27, 2023 - Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.
0
Company News for Dec 27, 2023
https://www.zacks.com/stock/news/2202486/company-news-for-dec-27-2023?cid=CS-ZC-FT-corporate_summary-2202486
Dec 27, 2023 - Companies In The Article Are: INTC,RYZB,BMY,NIO,MANU
0
Company News for Dec 26, 2023
https://www.zacks.com/stock/news/2202100/company-news-for-dec-26-2023?cid=CS-ZC-FT-corporate_summary-2202100
Dec 26, 2023 - Companies In The Articles: KRTX, BMY, NKE, TCEHY, RKLB
0
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B
https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201667
Dec 22, 2023 - Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
0
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024
https://www.zacks.com/stock/news/2201005/3-cancer-focused-biotechs-that-appear-promising-bets-for-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2201005
Dec 21, 2023 - With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.
0
Top Stock Reports for Microsoft, Booking Holdings & Bristol-Myers Squibb
https://www.zacks.com/commentary/2200541/top-stock-reports-for-microsoft-booking-holdings-bristol-myers-squibb?cid=CS-ZC-FT-research_daily-2200541
Dec 20, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Booking Holdings Inc. (BKNG) and Bristol-Myers Squibb Company (BMY).
0
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug
https://www.zacks.com/stock/news/2196867/bristol-myers-bmy-partners-with-systimmune-for-oncology-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196867
Dec 12, 2023 - Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.
0